Haitong Securities(600837) 证券之星·2025-03-27 14:39Core Viewpoint - The report outlines the fundraising and usage status of Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. for the year 2024, confirming compliance with regulatory requirements and detailing the management of raised funds [1][6][7]. Fundraising Overview - The company raised a total of RMB 1,074 million through the issuance of 12 million shares at RMB 8.95 per share, with net proceeds amounting to RMB 974.32 million after deducting issuance costs of RMB 99.68 million [1][3]. - As of December 31, 2024, the total amount used from the raised funds was RMB 486.36 million, with an additional RMB 346.45 million from over-raised funds permanently supplementing working capital [1][3]. Fund Usage and Management - The company utilized RMB 15.24 million of the raised funds during the reporting period and had a remaining balance of RMB 193.10 million in the dedicated account as of December 31, 2024 [1][3]. - A three-party supervision agreement was signed with banks to ensure proper management of the raised funds, and the company has adhered to its internal management procedures [1][4]. Cash Management - The company approved the use of up to RMB 250 million of temporarily idle raised funds for cash management, focusing on safe and liquid investment products [4][8]. - The company engaged in structured deposits and achieved returns from these investments, with no remaining balance in investment products as of the end of the reporting period [5][8]. Compliance and Audit - The report confirms that the company has complied with all relevant regulations regarding the management and usage of raised funds, with no violations reported [6][7]. - The auditing firm PwC provided a verification report affirming that the fundraising and usage report accurately reflects the company's financial activities [6][7].